Among 119 tested compounds, naringin was one of the promising compounds as an AChE, BChE, and BACE-1 blocker because, in the molecular docking study, naringin exhibited high binding affinity relative to donepezil and elenbecestat, the AD drugs [37]. The gene discussed is BACE1; the disease is Alzheimer disease.